Neuro-Oncology Multidisciplinary Tumor Board: The Point of View of the Neuroradiologist

Abstract

Background: The multi-disciplinary tumor board (MTB) is essential to quality cancer care and currently recommended to offer the best personalized clinical approach, but little has been published regarding MTBs in neuro-oncology (nMTBs). The aim of the present paper is to describe our nMTB, to evaluate its impact on clinical management decisions, and to assess the role of neuroradiologists. Methods: The retrospective evaluation of the cases discussed at our nMTB from March 2017 to March 2020. From the electronic records, we extracted epidemiological, clinical and other specific data of nMTB. From the radiological records, we calculated data relating to the number, time for revision, and other specifications of MRI re-evaluation. Statistical analysis was performed. Results: a total of 447 discussions were analyzed, representing 342 patients. The requests for case evaluations came from radiation oncologists (58.8%) and neurosurgeons (40.5%), and were mainly addressed to the neuroradiologist (73.8%). The most frequent questions were about the treatment’s changes (64.4%). The change in patient treatment was reported in 40.5% of cases, 76.8% of these were based on the neuroradiologic assessment. A total of 1514 MRI examinations were re-evaluated, employing approximately 67 h overall. The median of the MRI exams reviewed per patient was 3 (min–max 1–12). Conclusions: Our study supported that the multidisciplinary approach to patient care can be particularly effective in managing brain tumors. A review by an expert neuroradiologist impacts patient management in the context of nMTBs, but has costs in terms of the time and effort spent preparing for it.

Neurosurgical Defeats: Critically Ill Patients and the Role of Palliative Care Service

“…Still, the vast majority of those patients were able to complete the standard adjuvant treatment. This observation relativizes the importance of plain numbers; though the KPS score and age are important prognostic parameters, indication for surgery in fragile patients should be decided by the multidisciplinary brain tumor board, as routinely happens at our institution [ 6 ]. During the multidisciplinary meeting, the patient’s clinical history is thoroughly illustrated by the referral physician, and all possible therapeutic options are evaluated.…”

Building Team Medicine in the Management of CNS Metastases

“…In oncology, tumor boards have been established as a means of improving accuracy in diagnosis, bettering adherence to clinical guidelines, advancing the integration of novel research and clinical trials in clinical management, and improving patient outcomes [ 76 ]. Prior studies have demonstrated that multidisciplinary tumor boards improve both the quality of medical services offered to patients as well as OS rates [ 77 , 78 , 79 , 80 ].…”

A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

“…Although brain cancers exhibit a wide range of neoplasms, including limited or metastatic forms, the standard treatment commonly includes surgery, chemotherapy, radiotherapy, and immunotherapy. Chemotherapy for CNS cancers is still regarded as one of the most challenging treatments in the clinic (Gaudino et al, 2022; Ghajar‐Rahimi et al, 2022; H. S. Kim & Lee, 2022; Koekkoek et al, 2023; Lutz et al, 2022). Despite new anticancer drug developments in recent years, the prognosis for brain cancer patients, particularly those with malignant tumors, has remained poor (Koekkoek et al, 2023).…”